Nantes, France — September 8, 2025 — Leads & Copy — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has provided an update on ongoing proceedings ahead of its Shareholders’ Annual General Meeting on September 30, 2025. Following a hearing before the Nantes Commercial Court, the court is reviewing the regularity of the declaration of concerted action by a group of minority shareholders, with a decision expected on September 23, 2025.
The procedure aims to safeguard the integrity of the voting process at the AGM, ensuring all shareholders can exercise their rights under fair, transparent, and informed conditions. OSE Immunotherapeutics is committed to defending the interests of the company and its shareholders and will provide updates as available.
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology and immuno-inflammation, partnering with academic institutions and biopharmaceutical companies. The company is based between Nantes and Paris and is quoted on Euronext.
Contacts:
Fiona Olivier: fiona.olivier@ose-immuno.com
Sylvie Détry: sylvie.detry@ose-immuno.com
France Contact Media: Florence Portejoie, fportejoie@fp2com.fr, +33 6 07 768 283
U.S. Contact Media: Kate Barrette, kbarrette@rooneypartners.com, +1 212 223 0561
Source: OSE Immunotherapeutics
